Peptic Ulcer News and Research

RSS

A peptic ulcer, also known as PUD or peptic ulcer disease, is an ulcer (defined as mucosal erosions equal to or greater than 0.5 cm) of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.

ICU patients less likely to renew prescriptions for chronic diseases after discharge

Patients often do not renew prescriptions for their chronic diseases after they are released from hospital.

25 Aug 2011

China Shenghuo second quarter total revenue increases 58% to $10.9 million

China Shenghuo Pharmaceutical Holdings, Inc., today reported unaudited financial results for the second quarter ended June 30, 2011.

16 Aug 2011

Researchers, policy experts to examine issue of declining enrollment in clinical trials

Leading researchers and policy experts from across the country will come together June 27 and June 28 at Mount Sinai School of Medicine in New York to examine the issue of declining enrollment in clinical trials.

28 Jun 2011

Transarterial embolization an effective alternative to endoscopy for acute peptic ulcer bleeding

Researchers from China report that in patients with peptic ulcer bleeding in whom endoscopy failed to control the bleeding, transarterial embolization is a safe procedure which reduces the need for surgery without increasing overall mortality and is associated with few complications.

24 May 2011

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.

21 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

H. pylori DNA may help treat severe colitis

DNA from Helicobacter pylori, a common stomach bacteria, minimizes the effects of colitis in mice, according to a new study by University of Michigan Medical School scientists.

6 May 2011

Empire implements AGA, ACG guidelines for evaluation and management of dyspepsia and PUD

Empire BlueCross BlueShield today announced an initiative to inform and educate physicians and consumers about important findings from the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) related to a little known but common infection that is a precursor to serious stomach ailments.

7 Apr 2011

UTHealth study: Children with H. pylori infection have lower levels of iron

Children without previous iron deficiencies or anemia who remained infected with Helicobacter pylori had significantly lower levels of iron compared to children who had the infection eradicated, according to researchers at The University of Texas Health Science Center at Houston.

8 Mar 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

China Shenghuo's Lixuwang product recieves Chinese Well-Known Trademark Honor

China Shenghuo Pharmaceutical Holdings, a China-based pharmaceutical company engaged in the research, development, manufacture, and marketing of Traditional Chinese Medicine, nutritional supplement and cosmetic products, today announced that "Lixuwang", the trademark of its best selling product, Xuesaitong Capsule, was awarded the Chinese Well-Known Trademark Honor by the State Administration for Industry and Commerce of China.

24 Jan 2011

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

Sequella files SQ109 IND for Phase 2 studies in H. pylori-related duodenal ulcers

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced it has successfully filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to test SQ109 in patients suffering from H. pylori-related duodenal ulcers, and can now begin Phase 2 studies.

7 Dec 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

Using proton pump inhibitors and antiplatelet drugs (thienopyridines) together is an appropriate way of treating patients with cardiovascular disease who are at high risk of upper gastrointestinal bleeds, despite recent concerns about an adverse interaction between these two types of drugs, according to an Expert Consensus Document released jointly today by the American College of Cardiology Foundation, the American College of Gastroenterology, and the American Heart Association.

10 Nov 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Study finds hemostatic powder effective in treating 95% of patients with bleeding peptic ulcers

A new material similar to that used by the U.S. Military to treat traumatic injuries is showing promise as the next novel treatment for bleeding ulcers, a condition that commonly affects up to 15 per cent of adults, according to Hong Kong physician Dr. James Lau.

14 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010